Today announced that it has entered into a special global contract with Chatham Therapeutics.

The collaboration will allow Baxter to investigate Chatham’s Biological Nano ParticlesTM , an advanced recombinant adeno-associated virus- based gene therapy technology which has shown potential therapeutic benefit in early clinical studies. A small independent study involving six individuals using Chatham technology components was this issue of a 2011 article in THE BRAND NEW England Journal of Medicine. This contract shall involve another generation of the gene therapy technology, which Chatham and Baxter will investigate through U.S.-structured hemophilia B clinical trials. Baxter has obtained global rights for the commercialization and advertising of the new treatment. Related StoriesStudy suggests potential fresh way to block cancer-causing geneLeptin gene therapy helps weight reduction without significant side effect of bone lossScalable production of gene therapy vectors: an interview with Frank Ubags ”This collaboration demonstrates Baxter’s ongoing dedication to scientific invention in advancing treatment plans for patients living with hemophilia.The American Cancer Society says that if all adults between ages 25 and 64 acquired the cancer mortality rates of the greatest educated Americans, more than 60-thousand additional deaths out of this pervasive disease could be avoided. Click here to view the report, Cancer Specifics & Figures 2011.

, have access to an on-site concierge right now service supplied by Best Upon Request, a national organization based in Cincinnati. In reducing the demands and tension of everyday life, more than 2,700 associates at SJRMC may get in touch with the concierges to demand errand running, car providers, food shopping, event planning, information research and even more. This is a real way we are able to return the favor and look after our workers. That is a way we can return the favor and take care of our employees.